Dimed: Sales up 14.3%, digital and private label surged, EBITDA and cash flow improved, outlook strong

About this update from Dimed S.a. Distribuidora De Medicamentos

Q3 2025 saw strong sales growth of 14.3%, robust digital expansion, and a 32.6% rise in private label sales. EBITDA and cash flow improved, while net income was impacted by higher interest rates. The outlook remains positive, with continued focus on digital, private label, and generics.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Dimed S.a. Distribuidora De Medicamentos